ORAL DRUG DELIVERY SOLUTIONS

• Pharmaceutical Development

  Developing an optimized formulation tailored to your API nanoparticles is critical to unlocking their full potential.

• Controlled Expansion Of Supercritical Solutions (CESS®) Technology

  Nanoform’s award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology is a bottom-up nanoparticle engineering approach that enables the creation of API nanoparticles and can unlock the full therapeutic potential of small molecule drugs.

• Global Experts In Nanotechnology And Drug Particle Engineering

  Discover the nanoparticle engineering, formulation and GMP manufacturing services that can drive forward your market success and unlock the power of “small."

• End-To-End Drug Development, Analytical Testing, & Fill/Finish

  August Bioservices is a US-based, quality-driven CDMO that offers end-to-end drug development, analytical testing, and fill/finish manufacturing services to clients of all sizes and stages, from pre-clinical to commercial.

• Modified-Release Formulation Strategies

  Learn what oral modified-release (MR) dosage forms can offer and why they continue to rise in popularity.

• Sterile Formulation Development

  With over 20 years of experience, PCI’s strength lies in our ability to manage products with unique challenges ranging from small molecules presenting with solubility issues or a labile molecule that is only stable as a liquid presentation for a short time.

• Formulation Strategies For Poorly Soluble Molecules

  As the number of poorly soluble compounds continues to increase in the industry development pipeline, conventional formulation strategies may not be sufficient to achieve acceptable levels of solubility in the gastrointestinal tract and hence absorption into the systemic circulation.

• Pre-Formulation And Material Sciences

  Our formulation development and material sciences experts have over 30 years’ experience in pre-formulation and solid state characterization.

• cGMP Aseptic Manufacturing And Sterile Fill-Finish

  Experienced CDMOs will implement a cGMP aseptic manufacturing and sterile fill-finish policy to improve drug bioavailability. Aseptic fill-finish is a process in which the drug product, container, and container closure are sterilized separately and then integrated. Combining the drug, container, and closure in a clean room using special equipment that is self-contained in a sterile environment meets FDA guidelines related to cGMP.

• Rapid Development Through Phase I CTM

  Ascendia works with discovery-stage pharmaceutical companies to provide lab-scale formulations suitable for pre-clinical testing. We conduct pre-formulation assessments, bioavailability modeling, and formulation approach comparisons. We provide trial formulations suitable for animal studies, toxicology studies, and cGMP clinical trial materials for Phase I studies.